Aytu BioPharma (NASDAQ:AYTU) Issues Earnings Results, Misses Estimates By $0.37 EPS

Aytu BioPharma (NASDAQ:AYTU) issued its quarterly earnings results on Thursday. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.37), Zacks reports. Aytu BioPharma had a negative net margin of 14.60% and a negative return on equity of 31.31%. The business had revenue of $17.98 million during the quarter.

Aytu BioPharma Stock Performance

NASDAQ AYTU traded down $0.49 during trading hours on Friday, hitting $2.36. 237,675 shares of the company traded hands, compared to its average volume of 20,737. The stock has a market capitalization of $14.09 million, a price-to-earnings ratio of -0.90 and a beta of -1.43. Aytu BioPharma has a twelve month low of $1.87 and a twelve month high of $3.50. The business’s 50-day moving average is $2.52 and its 200-day moving average is $2.82.

About Aytu BioPharma

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.